Entereg Fails Phase III Trial; Adolor/GSK To Re-Examine Placebo Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing results throw into question the timing of sNDA submission.
You may also be interested in...
Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review
FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.
Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review
FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.
GSK/Adolor To Begin New Phase III Entereg Trial In Opioid-Induced Bowel Dysfunction
Companies also anticipate submitting “complete response” to FDA for postoperative ileus indication in second quarter.